PRNewsWire
29 Jun 2026, 08:25 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
Immutep Limited (IMMP) is facing a class action lawsuit alleging it made false and misleading statements regarding the TACTI-004 trial of eftilagimod alfa. — Securities litigation alleging the concealment of failed clinical trial endpoints creates significant regulatory and financial risk for biotech companies.
-0.60The lawsuit claims that despite reporting 'strong operational progress' in January 2026, Immutep knew the TACTI-004 trial would fail to meet primary efficacy endpoints. — Specific allegations of data manipulation or withholding trial failure results directly undermine the valuation of the company's primary drug pipeline.
-0.50Which stocks this story touches
The company is mentioned as being sued for securities law violations.
Continue reading
6 related stories
Top 3 movers · tap to explore
The company is mentioned as being sued for securities law violations.
The company is facing a class action lawsuit alleging false and misleading statements regarding trial efficacy.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
3h ago
